Browsing Tag
Lilly
33 posts
Lilly announces promising updates on olomorasib in KRAS G12C-mutant cancers at ASCO 2024
Eli Lilly and Company (Lilly, NYSE: LLY) has released updated data from its ongoing Phase 1/2 clinical trial…
Lilly to expand Indiana facility with record $5.3bn investment to boost production of APIs
In a historic move for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has announced a staggering…
Lilly announces significant results in SURMOUNT-OSA trials of tirzepatide in OSA
Eli Lilly and Company (NYSE: LLY) has released positive topline results from the phase 3 SURMOUNT-OSA clinical trials,…
Akouos AK-OTOF yields positive results in hearing restoration Phase 1/2 study
In a significant advancement for medical science and hearing loss treatment, Akouos, Inc., a wholly owned subsidiary of…
Lilly’s Zepbound marks remarkable weight loss milestone in SURMOUNT-4 study
In a significant development in the field of obesity treatment, Lilly’s Zepbound (tirzepatide) has shown remarkable results in…
Eli Lilly and Company announces first Lilly Gateway Labs facility in San Diego for 2024
In a strategic move to strengthen its position in the life sciences sector, Eli Lilly and Company (NYSE:…
Lilly announces $2.5bn high-tech manufacturing site in Alzey, Germany
Eli Lilly and Company (NYSE: LLY) unveiled its plan to build a $2.5 billion state-of-the-art manufacturing site in…
Lilly bags Zepbound FDA approval for obesity treatment
The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Zepbound (tirzepatide) injection, making it the…
FDA approves Lilly’s Omvoh: A breakthrough for ulcerative colitis treatment
The U.S. Food and Drug Administration (FDA) has sanctioned Eli Lilly and Company’s Omvoh (mirikizumab-mrkz) infusion (300 mg/15…
Lilly’s Retevmo outperforms in trials for RET fusion-positive NSCLC and RET-mutant MTC
Eli Lilly (Lilly) has disclosed the results from two pivotal Phase 3 studies, LIBRETTO-431 and LIBRETTO-531, evaluating the…